TABLE 2.
Clinical characteristics of control subjectsa
| Patient no. (age [yr], sex) | Hematological malignancy | Infection | Duration of neutropenia (days) | Platelia test results
|
Treatment | |
|---|---|---|---|---|---|---|
| Antigen (ng/ml) | Antibody (AU) | |||||
| C1 (45, F) | AML | Septicemia (Pseudomonas fluorescens) | 6 | 0.14, 0.11, 0.11, 0.14 | 0, 0, 0, 0 | Autologous stem cell transplantation |
| C2 (54, M) | NHL | Septicemia (S. epidermidis) | 11 | 0.15, 0.14, 0.13, 0.13 | 5.5, 5.4, 4.7, 4.4 | Autologous stem cell transplantation |
| C3 (21, M) | AML | Septicemia (S. epidermidis) | 32 | 0.14, 0.17, 0.11, 0.2 | 0, 0, 0, 0 | Chemotherapy |
| C4 (60, M) | NHL | Septicemia (Pseudomonas aeruginosa) | 7 | 0.13, 0.12, 0.12, 0.47 | 0, 0, 0, 2.4 | Autologous stem cell transplantation |
| C5 (41, M) | AML | Invasive aspergillosis (A. fumigatus) | 14 | 0.13, 0.1, 0.19, 0.19 | 0.7, 0.4, 0.9, 2 | Chemotherapy |
| C6 (66, M) | AML | Invasive aspergillosis (A. fumigatus) | 18 | 0.16, 0.18, 0.15, 0.44 | 0.5, 1.6, 2.4, 0.95 | Chemotherapy |
| C7 (7, F) | AML | Invasive aspergillosis (A. fumigatus) | 32 | 0.18, 0.1, 0.22, 0.5b | 0, 0.7, 0.9, 2.9 | Chemotherapy |
| C8 (8, M) | NHL | Invasive aspergillosis (A. fumigatus) | 57 | 0.16, 0.15, 0.17, 0.35 | 0, 0, 0, 0.5 | Chemotherapy |
| C9 (58, F) | Myeloma | None | 17 | 0.31, 0.16, 0.27, 0.2 | 0, 0, 0, 0 | Chemotherapy |
| C10 (42, M) | Myelodysplastic syndrome in transformation | None | 6 | 0.14, 0.25, 0, 0.17 | 3.5, 2.5, 1.7, 3.8 | Chemotherapy |
| C11 (75, M) | Myeloma | None | 5 | 0.17, 0.1, 0.19, 0.12 | 9, 9.3, 6, 7.2 | Autologous stem cell transplantation |
| C12 (57, M) | LMC | None | 9 | 0.17, 0.15, 0.16, 0.14 | 0, 0, 0, 0.3, 0.2 | Chemotherapy |
a
Abbreviations: F, female; M, male; AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; NHL, non-Hodgkin's lymphoma; LMC, chronic myeloid leukemia.
b
The value of 0.5 was above the cutoff value, indicating a positive result.